{
    "root": "bf2e0d62-5f93-4a04-852b-829296b5bdd2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Torisel",
    "value": "20250321",
    "ingredients": [],
    "indications": "torisel indicated treatment advanced renal cell carcinoma .",
    "contraindications": "\u2022 recommended dose torisel 25 mg administered intravenous infusion 30\u201360 minute period week . treat disease progression unacceptable toxicity . ( 2.1 ) \u2022 antihistamine pre-treatment recommended . ( 2.2 ) \u2022 dose reduction required patients mild hepatic impairment . ( 2.4 ) \u2022 torisel ( temsirolimus ) injection vial contents must first diluted enclosed diluent diluting resultant solution 250 ml 0.9 % sodium chloride injection . ( 2.5 )",
    "warningsAndPrecautions": "ndc 0008-1179-01 torisel ( temsirolimus ) injection , 25 mg/ml .",
    "adverseReactions": "torisel contraindicated patients bilirubin > 1.5\u00d7uln [ ( 5.2 ) ] .",
    "indications_original": "TORISEL is indicated for the treatment of advanced renal cell carcinoma.",
    "contraindications_original": "\u2022 The recommended dose of TORISEL is 25 mg administered as an intravenous infusion over a 30\u201360 minute period once a week. Treat until disease progression or unacceptable toxicity. ( 2.1 ) \u2022 Antihistamine pre-treatment is recommended. ( 2.2 ) \u2022 Dose reduction is required in patients with mild hepatic impairment. ( 2.4 ) \u2022 TORISEL (temsirolimus) injection vial contents must first be diluted with the enclosed diluent before diluting the resultant solution with 250 mL of 0.9% Sodium Chloride Injection. ( 2.5 )",
    "warningsAndPrecautions_original": "NDC 0008-1179-01 TORISEL (temsirolimus) injection, 25 mg/mL.",
    "adverseReactions_original": "TORISEL is contraindicated in patients with bilirubin >1.5\u00d7ULN [see Warnings and Precautions (5.2)]."
}